



PTO/SB/08B (02-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/769,579
Filing Date	January 25, 2001
First Named Inventor	Hector F. DeLuca
Art Unit	1617
Examiner Name	K. Stiller
Attorney Docket Number	960296.95700

RECEIVED
APR 17 2003
TECH CENTER 1600/2900

Sheet 2 of 2

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	✓	A. Al-Qadreh, et al., "Treatment of Osteopenia in Children with Insulin-Dependent Diabetes Mellitus: The Effect of 1alpha-Hydroxyvitamin D3," Eur. J. Pediatr. 155:15-17, 1996.	
	✓	C. Mathieu, et al., "Prevention of Type I Diabetes in Nod Mice by 1,25 Dihydroxyvitamin D3 and its Analogues," Proceedings of the Workshop on Vitamin D, pp. 540-548 1994.	
	✓	Y. Yoshida, et al., "A Randomized Study of Alfacalcidol in the Refractory Myelodysplastic Anaemias. A Japanese Cooperative Study," Int. J. Clin. Pharm. Res. XIII(1):21-27, 1993.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.